农林牧渔 农业周报 20260208-20260214：猪价快速调整，粮价稳步上涨 2026 年 02 月 23 日 行业周报 看好/维持 农林牧渔 走势比较 (10%) (2%) 6% 14% 22% 30% 25/2/24 25/5/5 25/7/14 25/9/22 25/12/1 26/2/9 子行业评级 | 种植业 | 无评级 | | --- | --- | | 畜牧业 | 无评级 | | 林业 | 无评级 | | 渔业 | 无评级 | | 农 产 品 加 工 | 无评级 | | Ⅱ | | 推荐公司及评级 | 中宠股份 | 买入 | | --- | --- | | 牧原股份 | 买入 | | 苏垦农发 | 买入 | 相关研究报告 <<登海业绩预告点评：降本+转基因 驱动，业绩拐点基本确立>>--2026- 02-11 <<天康业绩预告点评：全产业链韧性 支撑底部企稳，并购驱动扩张>>-- 2026-02-10 <<农业周报 20260201-20260207：一 号文发布，重视农业投资机会>>-- 2026-02-10 证券分析师：程晓东 电话：010-88321761 E-MAIL：chengx ...

2026 年 02 月 25 日 国产替代浪潮下的宠物药苗行业：发展路径、范 式解构与机遇洞察 推荐(维持) 投资要点 | 分析师：娄倩 | S1050524070002 | | --- | --- | | louqian@cfsc.com.cn | | | 行业相对表现 | | | 表现 | 1M | 3M | 12M | | --- | --- | --- | --- | | 动物保健Ⅱ(申 | -4.9 | 9.9 | 63.0 | | 万) | | | | | 沪深 300 | 0.1 | 4.8 | 19.9 | 市场表现 -20 0 20 40 60 80 100 (%) 动物保健Ⅱ 沪深300 资料来源：Wind，华鑫证券研究 相关研究 1、《动物保健Ⅱ行业深度报告：宠 物医院赛道将迎第一股，盈利拐点 转折时》2026-02-19 2、《从美日宠物医院行业复盘看国 内连锁率提升，以降本+复购+标准 化模式打造头部扩张潜力与高营 收》2025-09-05 ▌ 国产替代的范式解构：理论框架、演进路径与跨 行业验证 国产品牌的崛起遵循清晰路径：1）0-1 突破期：核心是以 "稳定质价比"结合渠道创新， ...

Investment Rating - The overall investment rating for the agriculture industry is "Positive" [6][10]. Core Insights - The report emphasizes the importance of agricultural investment opportunities following the release of the central government's No. 1 document, which highlights the need for comprehensive capacity regulation in the pig farming industry [5][19]. - The report identifies potential investment opportunities in the livestock and planting sectors, particularly focusing on companies with low valuations and strong growth potential [6][10]. Summary by Relevant Sections Livestock Industry - **Pig Farming**: The average price for pigs is 12.14 CNY/kg, a slight decrease of 0.16 CNY from the previous week. The average price for piglets is 29.24 CNY/kg, which increased by 0.62 CNY [5][19]. The industry is experiencing a gradual reduction in production capacity, with the number of breeding sows decreasing by 2.9% year-on-year [6][20]. - **Chicken Farming**: The average price for broiler chickens is 14 CNY/kg, reflecting a 0.3 CNY increase. However, the industry is facing challenges with profitability, as the average loss per chicken is 0.26 CNY [21][22]. The report suggests that chicken prices may remain volatile in the medium term due to high production levels [21][22]. - **Investment Recommendations**: Companies such as Zhongchong Co., Muyuan Foods, and Suqian Agricultural Development are rated as "Buy" due to their strong market positions and growth potential [3][10]. Planting Industry - **Seed Industry**: The No. 1 document promotes the industrialization of biotechnology in agriculture, which is expected to enhance the seed supply chain and improve the market environment for genetically modified crops [11][23]. The report gives a positive rating for the seed industry, highlighting the long-term investment value of leading companies [11][23]. - **Grain Prices**: Recent trends indicate that grain prices are likely to continue rising due to increased demand and reduced supply. The average price for corn is 2394 CNY/ton, and for wheat, it is 2531 CNY/ton, both showing slight increases [12][24]. The report suggests focusing on investment opportunities in the planting sector, particularly in companies like Suqian Agricultural Development [12][24].

Market Review - The agricultural index increased by 1.82% this week, outperforming the Shanghai Composite Index which fell by 0.44% and the Shenzhen Component Index which dropped by 1.61% [1] - All secondary industries within agriculture saw gains, with planting and feed industries leading at 9.44% and 1.76% respectively [1] - The top 10 gainers were primarily in the planting sector, while the top 10 losers were concentrated in the breeding sector [1] Core Insights Breeding Industry Chain - Pig Prices: The national average price for live pigs is 12.3 yuan/kg, down by 0.67 yuan from last week; the average price for piglets is 28.62 yuan/kg, up by 0.59 yuan [2] - Slaughtering Rates: The operating rate of large-scale slaughterhouses is 39.69%, up by 3.21 percentage points from last week and 12.3 percentage points year-on-year [2] - Production Capacity: By December 2025, 16 listed pig farming companies are expected to have a total output of 17.9 million pigs, a 2.9% increase quarter-on-quarter and a 1.35% increase year-on-year [2][3] Industry Recovery - The pig farming industry is experiencing a slowdown in capacity reduction, with the number of breeding sows at 39.61 million, down by 116,000 year-on-year [3] - Market pressures and potential policy changes are expected to impact the industry negatively in the near term [3] Individual Stock Valuation - Most listed breeding companies are currently valued at historical lows, indicating significant long-term investment potential [4] - The chicken industry is experiencing price fluctuations, with the average price for broiler chickens at 3.83 yuan/kg, up by 0.17 yuan from last week [4][5] Planting Industry Chain - Seed Industry: The strategic importance of the seed industry is recognized, with ongoing policy optimization and advancements in genetically modified organisms expected to boost seed prices [10] - Grain Prices: Recent demand and planting sentiment have led to price increases in various grains, with corn averaging 2390 yuan/ton and wheat at 2529 yuan/ton [12] Industry Data - The average price for live pigs is 12.3 yuan/kg, down by 0.67 yuan; the average price for broiler chickens is 3.83 yuan/kg, up by 0.17 yuan [13] - The average price for chicken feed remains stable at 3.45 yuan/kg, while the average price for corn is 2390 yuan/ton, reflecting a recent increase [13]

农业板块迎来行情催化，农发种业开盘10分钟内封死涨停，相关种业个股同步异动，板块整体表现活 跃。此次行情发酵源于两方面因素，一是农产品涨价预期逐步升温，生猪、大豆等品种价格出现波动上 行迹象；二是年度相关政策进入预热阶段，市场对产业支持政策落地抱有期待。 养殖产业链：涵盖生猪、白鸡、黄鸡等细分领域，生猪产业当前处于产能缓慢去化阶段，能繁母猪存栏 仍略高于正常保有量，冬季非洲猪瘟疫情防控压力上升，行业盈利随猪价短期反弹有所修复；白鸡祖代 引种量维持高位，商品代供给宽松，养殖环节保持微利；黄鸡产能处于历史低位，供给偏紧叠加消费旺 季需求支撑，养殖盈利保持稳定，立华股份、温氏股份等企业凭借成本优势占据市场份额。 本文源自：市场资讯 种植产业链：种业领域政策持续优化，转基因技术产业化稳步推进，优质种子产品迭代升级带动行业结 构调整；粮价受国际市场美联储降息、库消比下降及国内最低收购价政策支撑呈现上涨趋势，玉米、小 麦收购价格震荡上行，种植企业收益随粮价波动调整，苏垦农发等种植主体凭借规模化种植优势，收益 稳定性较强，中长期配置价值凸显。 作者：观察君 动保产业链：兽用化药领域，泰妙菌素、泰万菌素等产品价格处于高位震荡 ...

Investment Rating - The overall industry investment rating is "Positive" for the planting and livestock sectors, "Neutral" for forestry and aquaculture, and "II" for agricultural product processing [7][8]. Core Insights - The pig price is experiencing a seasonal rebound, with the average price at 12.78 CNY/kg, a slight increase of 0.15 CNY from the previous week. However, the mid-term outlook remains pessimistic due to ongoing market pressures [6][23]. - The livestock industry is undergoing a capacity reduction, with the number of breeding sows decreasing to 39.90 million heads, down 1.1% month-on-month. This trend is expected to continue due to low market prices, rising epidemic risks, and policy pressures [7][24]. - The chicken industry is facing high capacity levels, with prices expected to fluctuate in the mid-term. The average price for broiler chickens is currently at 3.77 CNY/kg, reflecting a slight decrease [8][25]. - The yellow chicken market is anticipated to see price increases due to low production levels, with the average price at 12.95 CNY/kg [10][27]. - The veterinary medicine sector is experiencing a price rebound for key antibiotics, with a year-on-year increase of over 20% expected [11][27]. - The seed industry is benefiting from favorable policies and the advancement of genetically modified crops, which is expected to enhance sales and pricing for quality seed companies [13][28]. - Grain prices are projected to rise in the mid-term due to reduced imports and supportive domestic policies, with corn prices currently at 2369 CNY/ton [14][29]. Summary by Sections Livestock Industry - The average price for live pigs is 12.78 CNY/kg, with a slight increase of 0.15 CNY from last week. The average price for piglets is 25.14 CNY/kg, up 0.66 CNY [6][23]. - The operating rate of large-scale slaughterhouses is 38.58%, down 1.19 percentage points from last week [6][23]. - The number of breeding sows has decreased to 39.90 million heads, down 1.1% month-on-month, indicating a trend of capacity reduction [7][24]. Chicken Industry - The average price for broiler chickens is 3.77 CNY/kg, with a slight decrease of 0.03 CNY from last week [8][25]. - The industry is at a historically high capacity level, with prices expected to remain volatile in the mid-term [9][26]. - The yellow chicken market is expected to tighten supply, with prices likely to rise due to low production levels [10][27]. Veterinary Medicine - Key antibiotic prices are rebounding, with a year-on-year increase of over 20% expected [11][27]. - The market for veterinary vaccines is also growing, with increased sales anticipated for domestically produced vaccines [12][27]. Seed and Grain Industry - The seed industry is benefiting from favorable policies and advancements in genetically modified crops, which are expected to drive sales and pricing [13][28]. - Grain prices are projected to rise due to reduced imports and supportive domestic policies, with corn prices currently at 2369 CNY/ton [14][29].

Summary of the Conference Call for 瑞普生物 (Reap Bio) Company Overview - 瑞普生物 is engaged in the animal health industry, focusing on poultry products, vaccines, and pet care products. The company has shown resilience in its poultry segment and is optimizing its product structure with an increasing share of vaccine business [2][3]. Key Points Industry and Business Performance - The poultry products business remains the core driver of performance, with a significant contribution to overall revenue [2][3]. - Vaccine business has shifted from a 50:50 ratio with pharmaceuticals to a 60:40 ratio, indicating a substantial increase in vaccine sales [3]. - The pet care segment achieved record sales, nearing 1 billion yuan in 2025, marking the highest level in the company's history [3]. - The company has made breakthroughs in research and development, particularly in subunit vaccines and mRNA vaccines, with plans to launch industry-leading products [2][3]. Financial Performance and Challenges - In Q4 2025, the downturn in the pig farming sector exerted pressure on the company's continued use of formulations, but the poultry segment's profitability and emerging pet business mitigated the overall impact [2][4]. - The raw material drug business underperformed expectations, particularly with the price of florfenicol experiencing a downturn. The company plans to focus on high-margin products and optimize production capacity [2][5]. Strategic Initiatives - The company is enhancing its service model by providing comprehensive lifecycle services to major clients, which has helped maintain profitability despite market challenges [4]. - Plans to expand the customer base in the supply chain business to 20,000 pet hospitals and stores by 2028, aiming for total sales exceeding 2 billion yuan [3][8]. - The company is also pursuing international market expansion, with a goal for export revenue to account for at least 10% of total income in the next 3-5 years [11]. Product Development and Market Position - The cat trivalent vaccine is a core product in the pet segment, accounting for 30%-40% of sales, with plans for market share expansion through channel promotion and brand enhancement [6][7]. - The company is actively engaging with large-scale breeding and food processing enterprises to ensure stable growth in synthetic biology projects, particularly in the silk protein project, which has significant market potential [12]. Future Outlook - The company anticipates continued growth in the pet segment, with strong performance expected in Q4 2026, particularly during promotional events like Double Eleven [5]. - The overall strategy includes optimizing product structure and enhancing operational efficiency to sustain revenue and profit growth [3][4]. Miscellaneous - Non-operating income for Q4 is expected to be around 100 million yuan, primarily from government subsidies and investment income [10]. - The company is in the process of listing with 瑞派 (Ruipai) and has submitted necessary documentation to the Hong Kong Stock Exchange [9]. This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic initiatives, and future outlook in the animal health industry.

Group 1 - The core viewpoint of the article is that the company, BioShares (600201.SH), has confirmed that both its rabies vaccine and cat trivalent vaccine are currently on sale [1] - The cat trivalent vaccine has seen significant sales growth in the first three quarters, facilitated by a combination of online and offline sales strategies [1]

Group 1 - The core viewpoint of the article is that the company, Shengwu Co., Ltd. (600201.SH), has confirmed that both its rabies vaccine and cat trivalent vaccine are currently on sale [1] - The cat trivalent vaccine has seen significant sales growth in the first three quarters, attributed to the integration of online and offline sales channels [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a recovery in performance, with a focus on the orderly advancement of non-epidemic vaccine clinical trials. The revenue for Q1-Q3 2025 reached 1.042 billion yuan, a year-on-year increase of 7.38%, while the net profit attributable to shareholders was 161 million yuan, a year-on-year decrease of 4.85%. In Q3 alone, revenue was 423 million yuan, up 17.76% year-on-year, and net profit increased significantly by 116.40% year-on-year [2][3] - The company maintains its profit forecast for 2025-2027, expecting net profits of 188 million yuan, 352 million yuan, and 508 million yuan respectively, with corresponding EPS of 0.17 yuan, 0.32 yuan, and 0.46 yuan. The current stock price corresponds to PE ratios of 65.4, 35.0, and 24.3 times for the respective years [2] Summary by Sections Financial Performance - For Q1-Q3 2025, the company reported a revenue of 1.042 billion yuan, a 7.38% increase year-on-year, and a net profit of 161 million yuan, down 4.85% year-on-year. Q3 revenue was 423 million yuan, up 17.76% year-on-year, with net profit soaring by 116.40% year-on-year [2] - The company forecasts net profits of 188 million yuan in 2025, 352 million yuan in 2026, and 508 million yuan in 2027, with EPS projected at 0.17 yuan, 0.32 yuan, and 0.46 yuan respectively [2][3] Market Position and Growth - The company is expanding its market share in the competitive pig vaccine sector, with Q1-Q3 2025 sales of pig foot-and-mouth disease vaccines increasing by 50% year-on-year. The revenue from non-foot-and-mouth vaccines also saw significant growth, with diarrhea vaccine revenue up 120% year-on-year [3] - Direct sales channels for poultry vaccines showed strong performance, with a 40% year-on-year increase in direct sales revenue. The company is also expanding its international business, with revenue growth exceeding 16 million yuan in Q1-Q3 2025 [3] Research and Development - The company emphasizes stable operations and innovation in R&D, with R&D expenses of 96 million yuan in Q1-Q3 2025, a 9.08% increase year-on-year. The non-epidemic vaccine development is progressing, with the first clinical trial expected to begin by the end of December 2025 [4]